Current concepts of cystic fibrosis (CF) pathophysiology link ion transport abnormalities to reduced airway surface liquid (ASL) hydration and impaired mucus clearance. It is likely that correction of the defects that cause ASL dehydration will prevent degradation of mucus clearance, thereby preventing the initiation and/or progression of CF lung disease. A number of novel therapeutic agents aimed at the earliest steps in disease pathogenesis are now under development for the treatment of CF lung disease. Consequently, there is a tremendous need to develop methods that directly assess the effects of these agents on the underlying pathophysiologic process in the target organ. The measurement of mucociliary clearance (MCC) is a highly biologically relevant outcome, but one that is in need of further development. Here, we describe important methodologic aspects of MCC measurement and issues that have limited its use as an outcome measure in the past. Furthermore, we outline the steps that are being carried out now, and will be carried out in the future, to improve the performance of these studies in clinical trials. A systematic approach to optimizing and standardizing the measurement of MCC should greatly advance our ability to assess novel therapies at a relatively early stage of drug development. The resulting data may then be used to select those candidates that should be rapidly advanced into larger clinical trials.
development pipeline. A sensitive and specific outcome measure that directly reflects the mucus clearance defect in CF as well as the impact of effective therapies would, therefore, be an invaluable tool for the drug development process.
The measurement of mucociliary clearance (MCC) has, in fact, been performed for decades via various techniques. The inhalation of aerosolized, radiolabeled particles is the most widely accepted technique. However, significant variation exists in the nature of the inhaled particles, their delivery to the airway, and the analysis and interpretation of MCC studies, and has limited its acceptance as a reliable outcome measure. The ongoing development of CF therapies aimed at normalizing ASL hydration and mucus clearance makes refinement and validation of the MCC measurement technique an important priority for the CF research community. The ensuing text describes the current status of MCC measurements and further outlines the necessary refinements that will increase the utility of this outcome measure.
TECHNICAL ASPECTS OF MCC MEASUREMENTS
The measurement of MCC or cough clearance (CC) rate requires the delivery of an externally detectable and nonabsorbable marker to the airways. Past studies have utilized substances such as technetium-99m-labeled iron oxide and human serum albumin for this purpose. More recent studies have relied on the nebulized delivery of technetium sulfur colloid (Tc-SC) aerosols. The unfiltered form of Tc-SC contains submicronic particles (mean size, 0.3 m) (6) in isotonic saline. This solution is then nebulized to form larger aerosol particles that are inhaled. After delivery to the airways, minimal tracer penetration into the bloodstream is observed, and the bulk of the Tc-SC mass is thought to remain suspended within the mucus layer (7) . Luminal macrophages do, however, engulf a significant fraction of deposited particles within the time frame of a typical MCC study (31% after 100 min), but clearance of these macrophages is thought to occur at a similar rate to free Tc-SC particles (8) .
The lung deposition pattern of aerosolized particles depends upon the characteristics of the aerosol particles (average size, distribution of size), the breathing pattern used during inhalation (flow rate, tidal volume), and the nature of the airways themselves (i.e., degree of obstruction and lung size) (9) . This is critically important, because the observed rates of MCC vary in different lung regions, and, therefore, are highly dependent on the deposition pattern (10) . For example, MCC rates within small airways are on the order of 1 mm/minute, whereas rates in large airways and the trachea may be as high as 2 cm/minute (11) . Macrophage-mediated clearance of particulates deposited in the alveoli is much slower (i.e., months). Although the ability to manipulate aerosol characteristics and breathing patterns provides the opportunity to target and study different lung regions, the resulting variability in lung deposition also makes the generation of reproducible MCC data difficult. Therefore, an emphasis has been placed on devising aerosol delivery systems with a high degree of deposition pattern reproducibility, thereby reducing measurement error and increasing the ability to detect differences between groups. These systems typically use an aerosol generation device and a series of delivery adjuncts to produce repeatable breathing patterns and consistent aerosol dosing. For example, pneumotach devices with visual feedback are often used to control inhalation flow rate and tidal volume within specific ranges; metronomes can be used to guide the timing of inhalation and exhalation; and aerosol dosimetry equipment can be used to pulse aerosol delivery during specific portions of the breathing cycle.
Despite careful efforts to minimize the variability of aerosol deposition, significant differences that confound MCC data may still occur within a patient on consecutive studies or between groups of individuals. Therefore, it is very important that initial deposition patterns be quantified and factored into comparisons between studies. Deposition parameters are typically expressed as ratios of radioactive counts in central and peripheral lung zones made at the beginning of the clearance measurement period (C/P ratio). In principle, peripheral zones will comprise primarily slowly clearing small airways, whereas central regions, although also containing the small airways, will be relatively enriched with more rapidly clearing large airways. To define these lung regions, either a transmission scan (using an external radiation source) or a ventilation scan (using an inhaled radioactive gas, such as xenon-133) must be performed so that the outer lung boundaries can be identified and regions of interest assigned ( Figure 1A ). Once identified, the initial aerosol deposition image ( Figure 1B ) may be used to quantitate the C/P ratio. Clearance rates in each region (i.e., whole lung, central, peripheral) may then be expressed as a function of retained counts versus time. When a xenon-133 ventilation scan is used to define lung boundaries, the C/P ratio can be further normalized to the lung volume contained within each lung zone using the counts measured after achieving equilibrium during xenon inhalation (12) . Alternatively, deposition may be described using a parameter called the The effect of the ratio of radioactive counts measured in the central and peripheral lung zones (C/P ratio) on rates of mucociliary clearance, as denoted by particle retention through 120 minutes, in a cohort of normal study subjects. Images in (A ) and (B ), and data in (D ) (previously unpublished) courtesy of W.D. Bennett.
"penetration index" (PI). The PI is the ratio of radioactive counts per pixel area in the peripheral lung zone to counts per pixel area in the central zone (13) . Because increased deposition in central airways, as indexed by a high C/P ratio or low PI, is associated with increased rates of MCC, it is critical to account for this potential confounder in the analysis of these data ( Figure  1D ) (14) . A different approach to circumventing errors that result from differences in aerosol deposition focuses on clearance measured in the peripheral lung zone (12) . Because this region contains a somewhat more homogeneous composition of airways than the central or whole-lung regions, resulting clearance rates are expected to be less sensitive to the initial deposition pattern. This approach can be problematic, however, because reduced tracer deposition (with traditional delivery systems) and intrinsically slower clearance rates in this region lead to a smaller signal:noise ratio. Drug effects on central/larger airways may also be missed by this approach.
The temporal relationships between a particular intervention, the delivery of inhaled radiolabel, and the onset of imaging are also important considerations. This is particularly true because of the two-phase nature of clearance that is typically observed ( Figure 1C ) (7) . A fast clearance phase is usually noted immediately after the administration of the Tc-SC aerosol, lasting for a period of 15-40 minutes. A slower clearance phase is then observed, which lasts through the rest of most typical imaging periods (i.e., 1-2 h). It is thought that the fast phase of clearance represents the initial, rapid transit of deposited particles from larger airways, whereas the slow phase reflects small airway clearance. It is possible, however, that slower clearance phases could reflect the movement of the radiolabel into a less clearable compartment (e.g., due to mixing into the PCL vs. residence in the mucus layer, or intracellular uptake vs. free Tc-SC label), rather than being a function of airway deposition. The time between aerosol administration and the commencement of imaging will affect the proportion of the fast phase that is sampled, and could potentially have substantial effects on the overall measured rate. Comparative trials, therefore, must carefully match the time between Tc-SC delivery and the start of imaging.
Once subjects have inhaled the radiolabeled particles, they are positioned in front of a camera that detects and records emitted ␥ radiation. The sensitivity and spatial resolution of the resulting image will be a function of the inhaled Tc-SC dose, the camera resolution (i.e., pixel matrix size), and the thickness of the associated collimator. Collimators are thin plates that are placed between the patient and the detecting surface of the ␥ camera, which filter out "scatter," allowing only radiation coming from a direction perpendicular to the camera to reach the imaging surface (15) . In general, camera properties that improve resolution (more pixels/inch, thicker collimator) also reduce its sensitivity, causing a trade-off that can only be compensated by increasing the administered Tc activity. Longer acquisition times for each ␥ camera image will also improve the signal available for analysis while reducing the number of images (i.e., data points) that can be collected during the clearance measurement. Patient positioning during imaging is another factor that varies between centers, with some studies using seated positioning (16) and others using recumbent positioning (13) . Seated positioning provides for easier aerosol delivery and, arguably, a more physiologically realistic assessment. Recumbent positioning may improve subject comfort and minimize movement during imaging. Differences in rates of clearance as a result of patient position have not been explored. Finally, images used in the calculation of MCC must be corrected for decay of the isotope and for background radiation level. Typically, only the right lung is analyzed, because activity in the stomach can bias left-lung counts.
MCC measurements are often supplemented by measurements of CC, and by extended (i.e., 24-h) measurements of clearance. CC is typically measured by having the subjects cough at prescribed frequencies through an expiratory flow measurement device to gauge the forcefulness of each cough. In most cases, a period of CC is included some time after the initial measurement of MCC (16, 17) , although, in this configuration, the amount of isotope available in airways available to clearance by cough (i.e., more central airways) may be significantly reduced, thereby lowering the sensitivity of this measurement. Furthermore, because a preceding period of cilia-based clearance will have variably reduced the amount of isotope accessible to clearance by cough on different study days, a further normalization (e.g., C/P measured at start of coughs) must be used before comparing CC measurements. Current protocols for CC measurement in CF, therefore, are suboptimal, because study designs used to measure this clearance parameter have prioritized it below cilia-dependent clearance measurements.
Measurements of 24-hour clearance have gained renewed interest recently, and serve several purposes. First, they provide an additional means of assessing aerosol deposition pattern, because aerosol initially delivered to the alveoli will be retained for a much longer period than aerosol delivered to the airways (10, 18) . Second, these measurements can also be used to provide a measurement of cumulative clearance over longer time domains, which, in turn, may illustrate therapeutic efficacy (16) . The relative contribution of (1 ) alveolar deposition, (2 ) slowphase clearance from peripheral airways, and (3 ) mixing into a poorly cleared compartment of the ASL to 24-hour measures of clearance remains unclear. In addition, because the half-life of technetium-99m is approximately 6 hours, assessment of 24-hour clearance requires the delivery of sufficient initial tracer activity to ensure signal levels that are sufficiently above background at later timepoints.
MCC AS AN OUTCOME MEASURE IN CF
Comparison of MCC measurements in healthy subjects and patients with CF, as well as other accumulated experiences with MCC measurements in clinical trials, provides an opportunity to judge the ability of MCC measurement techniques to serve as a biomarker of disease and/or drug activity. In this section, we will review both positive and negative data pertinent to these issues, and will discuss important issues that should be addressed in future studies.
Several published comparisons of MCC measurements in unaffected individuals and subjects with CF are available for review. In the largest, by Robinson and colleagues, a retrospective review of one laboratory's experience in normal subjects (n ϭ 17 subjects/22 studies) and subjects with CF (n ϭ 59 subjects/ 184 studies) was reported (13) . Salient features from this study include the fact that mucus clearance was indeed markedly impaired in subjects with CF in comparison to the normal cohort. This reduction in clearance in patients with CF was most apparent in central and intermediate regions (vs. peripheral) and in apical and "mid" zones (vs. basal). In each of the most affected regions, clearance was approximately 50% that of the normal rate. Interestingly, the observed reductions in clearance appeared to be independent of baseline lung function, and even a subgroup of subjects with CF with normal FEV 1 measurements (n ϭ 17) manifested markedly abnormal clearance rates. In other comparisons of clearance rates between unaffected individuals (n ϭ 12-17 each) and patients with CF with mild to moderate impairment in lung function (n ϭ 12-20 each), whole-lung clearance was, in fact, not different (12, 16) . However, MCC indices that reflect clearance from small airways, particularly peripheral zone clearance and 24-hour clearance, were significantly reduced (12, 16, 19) . Finally, a study of long-term clearance from CF airways used a delivery technique that specifically targeted small airways with a radiolabeled particle that allowed detection of clearance over a 3-week period. This study demonstrated significantly increased particle retention after 24-hours in subjects with CF (67 vs. 48%, CF vs. normal, respectively). Particle retention between 7 and 21 days was not affected. Although the authors contended that these data did not reflect a small airway clearance defect in CF, but, rather, reflected delayed clearance from large and medium-sized airways, this interpretation is debatable. In fact, because there was very little predicted large/medium-sized airway deposition with the inhalation technique used (20-25% of total deposited fraction), it would appear likely that delayed small airway clearance did indeed contribute to the difference in 24-hour retentions between normal subjects and those with CF. The lack of a difference between clearance after 7 days may signify that clearance mechanisms other than MCC (e.g., cellular uptake) are dominant over these longer time domains (20) . The sum of these data, therefore, support the hypothesis that a mucus clearance defect exists in CF, even in the setting of mild airway obstruction, but that this defect may be inhomogeneous and primarily localized to the small airway compartment at this stage of disease.
MCC measurements have now been used in a number of small clinical trials (Table 1 ). An acute stimulation of MCC was noted with several therapeutics that are now being developed for CF lung disease. These include hypertonic saline (HS) (16, 21) , mannitol (17), amiloride (22) , and uridine 5Ј-triphosphate (UTP) (12) . HS and mannitol, both osmotic agents, appeared to yield the largest acute stimulation of clearance, whereas UTP only accelerated peripheral lung clearance rates in patients with CF when combined with amiloride. MCC was also measured during repetitive dosing of HS in patients with CF, and demonstrated sustained improvements in clearance rates (i.e., Ͼ 8 h 
Definition of abbreviations:
ASL ϭ airway surface liquid; CC ϭ cough clearance; CF ϭ cystic fibrosis; C/P ϭ radioactive counts in central and peripheral lung zones; MCC ϭ mucociliary clearance; UTP ϭ uridine 5Ј-triphosphate.
after prior dose) within 2 weeks of initiating this therapy. In addition, an acute stimulation of clearance could still be observed at the end of the 2-week dosing period (i.e., no tachyphylaxis). Interestingly, the combination of amiloride and HS yielded acute, but not sustained, improvements in MCC, and did not improve lung function or symptoms, unlike HS alone, which did yield improvements in these clinical outcomes (16) . Given that HS not only improved lung function, but also has been shown to reduce the frequency of pulmonary exacerbations (23) , it is enticing to speculate that its sustained effect on MCC might in fact serve as a surrogate marker for improvement in one of these more traditional clinical outcomes. Clearly, though, this association will require additional study in order to validate a true causal link. Longer-acting and more potent analogs of UTP (denufosol tetrasodium; Inspire Pharmaceuticals, Inc., Durham, NC) and amiloride (PS 552-02; Parion Sciences, Inc., Durham, NC) are currently in development for CF, with the hope that these agents will also yield sustained improvements in MCC. Of note, PS 552-02 has been reported to improve MCC in normal subjects, and to have some evidence of pharmacodynamic durability (effect detectable at 4 h after dosing) (24) , whereas the effects of denufosol on MCC in humans are not yet known.
In contrast to these agents that have been shown to accelerate MCC rates, a variety of other therapeutics that were predicted to improve MCC in CF have failed to show measurable effects. Although these failures may truly reflect a lack of efficacy of the study agent, it must also be considered that improved MCC measurement techniques and/or study designs might have uncovered beneficial effects. Therefore, it is instructive to examine these studies as well. Drugs proposed to reduce the degradation of the CF transmembrane conductance regulator protein (i.e., sodium 4-phenylbutyric acid [25] ), increase ciliary beat frequency (i.e., terbutaline [26] and sodium bicarbonate [27] ), decrease the viscosity of the mucus (Pulmozyme [28] ; Genentech, Inc., South San Francisco, CA), or increase the ASL volume by stimulating chloride transport (Moli1901; Lantibio, Inc., Chapel Hill, NC) have been tested in patients with CF at different centers. Table 1 provides an outline of these studies, with potentially relevant shortcomings that prevented a positive outcome.
There are a number of possible explanations related to study design for the negative outcomes reported in these studies. First, the effect of a given drug may be short lived, and an effect on MCC may only be detected if the timing between dosing and MCC measurement is appropriate. If the pharmacodynamic properties of a drug are unknown, MCC assessments at acute and delayed time points after dosing may be required. Of note, the acute effects of sodium 4-phenylbutyric acid and Moli1901 on MCC were not assayed by nature of their respective study designs, and could account for the absence of any detectable effect on MCC. Second, as with any drug, an effective dose must be reached. This issue may be particularly problematic with inhaled therapies if formal drug delivery and pharmacokinetic information is not available before choosing a dose in "proof of mechanism" or therapeutic trials. Certainly the CF lung can be a particularly challenging target organ due to inhomogeneous ventilation/delivery and physical barriers posed to some drugs by a thickened mucus layer. Third, the MCC parameter being assessed should match the effect of the drug being delivered. For example, Pulmozyme may, in fact, alter sputum rheology in a fashion that predicts improved CC, but not cilia-dependent clearance (29) . Therefore, to capture the effect of this drug on mucus clearance, a dedicated CC study might be necessary rather than the typical MCC study format, where cough is either not measured, or is measured after 60-90 minutes of measuring ciliadependent clearance. Similar problems could also be encountered if an agent primarily affects clearance from small versus large airways and the MCC study (i.e., the radiolabeled aerosol delivery strategy) is not designed to assess this airway region. Finally, a large number of patient-and study-related factors might increase the variability of MCC measurements or otherwise reduce the ability to detect meaningful differences affected by a novel therapy. For example, one must consider the other therapies being used by a patient, including those that might affect the baseline rate of MCC or CC (e.g., HS or rhDNase, antibiotic therapies), or alter the deposition of the study drug and/or radiotracer (e.g., bronchodilators). Holding potentially confounding medications or treatments (i.e., mechanical airway clearance maneuvers), or at least standardizing their timing before MCC measurement, must be considered carefully. Unwanted variability may also be encountered in longer trials, given the intrinsic variability of CF lung disease, thereby reducing study power and increasing necessary sample size to detect clearance rate changes in both crossover and parallel-group designs. Given these inherent problems, study designs that carefully consider these factors, and analysis plans that account for common confounders, are essential.
FUTURE DIRECTIONS
Despite the importance of being able to accurately quantitate MCC/CC as an outcome for CF therapeutic trials, only a few CF centers have developed the capacity to perform these studies. Unfortunately, the techniques used to measure MCC/CC at these centers are not standardized, making comparison of results difficult at times. Furthermore, with the limited use of MCC measures as an assessment of clinical efficacy, no rigorous assessments of intrasubject variability for any of the currently used methodologies have been made. Because an increasing number of drugs designed to improve MCC/CC in CF are entering the therapeutic pipeline, it is vital to develop standard techniques for these measures in order to efficiently screen compounds at an early stage of development and rapidly advance those with the highest chance of being effective.
Perhaps the most important element to standardize of MCC/ CC studies is the delivery of the radiolabeled aerosol. Because clearance rates are highly dependent on regional deposition of the radiolabeled particles in the lung, aerosol delivery to the bronchial airways must occur in a reproducible manner to minimize intra-and intersubject variability in particle deposition. However, it is primarily these delivery methods that differ between various study sites. In an effort to address this problem, aerosol delivery techniques that have been shown to improve the reproducibility of deposition are currently being optimized and simplified in a multicenter effort supported by the CF Foundation. These studies are also aimed at the standardization of data acquisition and image analysis protocols for assessing initial, regional deposition patterns, and the subsequent retention-versustime MCC data. Finally, because serial studies will be performed, data pertinent to within-subject repeatability and betweencenter reproducibility will be generated. This collaborative effort should significantly advance efforts to make MCC measurements comparable at CF centers that are currently active in this field.
The current methods for measuring MCC are designed to target delivery of radiolabeled particles to the bronchial airways, but the observation times and inhalation maneuvers are such that the measured MCC rates are primarily reflective of the largest of these airways. On the other hand, because the initial pulmonary pathophysiology in CF occurs in the small, peripheral conducting airways (30) , it is likely that mucociliary dysfunction also begins there, as evidenced by two previously described comparisons of MCC in normal subjects and those with CF (12, 16 ). An inhalation method that has been employed to specifically target particle deposition to the small, bronchial airways is the extremely slow inhalation technique described by Anderson and colleagues (31) . These investigators had subjects inhale large particles, 6-m mass median aerodynamic diameter, with very low inhalation flow rates (0.04 L/s), conditions under which they predicted that these large particles would settle out in the small bronchial airways before reaching the alveolar region. The subsequent clearance kinetics that they measured through 96 hours after deposition supported this contention (i.e., a slow but significant clearance of particles from 24 to 96 hours, consistent with particle clearance from small airways. Incorporating such an inhalation method, along with retention measurements at later time points (6-24 h), into future studies may provide a better index of small airway clearance in CF for analysis of therapeutic effects in these airways. This may be particularly important for agents not expected to yield large, rapid ASL volume fluxes in central airways, and for drugs that preferentially affect small airways in CF, as was seen with the combination of UTP and amiloride (12) .
Although uncontrolled, spontaneous coughing can confound measures of MCC (32), more standardized, controlled measures of CC can be obtained by incorporating fixed numbers of voluntary coughs during the image acquisition period for assessing particle clearance (32, 33) . Because certain agents may change sputum rheology in a manner that preferentially improves this mucus clearance parameter (vs. cilia-dependent clearance), MCC/CC protocols that adequately measure CC are important. Of note, MCC/CC studies that are primarily focused on the measurement of CC have not been performed in CF, and previously used protocols have serious shortcomings in the assessment of this variable. The development of improved methodologies that incorporate standardized coughs at a time point closer to the delivery of radiolabel should be considered. Finally, spontaneous cough frequency, as a potential covariate in the analysis of MCC/CC, should also be recorded throughout the imaging period in all MCC/CC studies.
Other aspects of MCC study designs should also be considered in relation to the study drug's proposed action. For example, if a drug is thought to have an immediate effect on MCC/CC, does not alter airway mechanics, but does elicit spontaneous coughing during administration, the study drug dosing should occur immediately before the inhalation of radioaerosol and subsequent ␥ camera monitoring. On the other hand, if a drug acts acutely, but does alter airway mechanics (e.g., a bronchodilator) and doesn't elicit spontaneous cough, then dosing should occur immediately after inhalation of the radioaerosol to avoid differences in deposition pattern on drug and placebo study days. Finally, if a drug has a delayed onset while not affecting airway mechanics, then inhalation of radioaerosol should occur some time after inhalation of the drug (depending on peak effect or durability of the drug). As part of the preclinical trial development of new therapies to improve MCC/CC in CF, we recommend an acute, double-blinded, cross-over study design to first show biological effect. A positive outcome in such a trial may be followed by a longer design (e.g., 2 wk of repetitive dosing), similar to that recently performed for aerosolized HS (16) . Such a trial allows detection of MCC/CC changes (e.g., sustained effects on MCC rate) that might only occur with longer treatment periods, as well as comparison with other lung function endpoints.
CONCLUSIONS
The measurement of MCC and CC is a very promising, but incompletely developed, biomarker for CF clinical research. There is strong evidence that measurements of MCC/CC are biologically and clinically relevant, in that they have been shown to reflect the underlying disease process and to be responsive to therapies aimed at normalizing ASL volume (e.g., HS, mannitol, amiloride, UTP). In addition, this outcome measure has the distinct advantage of being an index of both disease activity and drug effect in the critical target organ, the lung, as opposed to other outcome measures that might be used in drug trials of ion channel-directed therapies (e.g., nasal potential difference or sweat chloride). As a result, a positive effect on MCC testing might be more likely to translate into clinical benefit than a nonpulmonary outcome. Shortcomings that are currently being addressed include the lack of procedural standardization between centers that can perform MCC. This has limited the ability to compare results of studies performed at different centers, and, more importantly, has limited our ability to perform multicenter studies of new CF therapies using MCC as an outcome.
Once a standard operating procedure is refined and agreed upon, it will be important to assess the repeatability and reproducibility of these studies to facilitate the appropriate design of clinical trials. It is possible, however, that a single MCC/CC protocol may not be adequate to address all aspects of mucus clearance, or be optimally suited for testing of all drugs in the development pipeline. Alternatively, several protocols could be created to assess different aspects of mucus transport (e.g., CC, small airway clearance), although each would need to be formally validated. Whether or not any particular aspect of an MCC assessment (e.g., a sustained effect on whole-lung clearance) will be shown to actually predict a clinically relevant outcome (e.g., reduced exacerbation frequency)-in other words, serve as a surrogate marker-is unclear, but would be an exciting development. Ultimately, dissemination of the ability to perform MCC measurements to other research centers should be feasible, and would greatly enhance the ability to test candidate CF therapies in a much more rapid and thorough fashion.
